CING
Cingulate Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.10
−2.30%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
Market Cap
$74.16M
MomentumView details →
1D Return
−2.30%
YTD Return
+17.74%
RSI (14)
47.5
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
Market Cap
$74.16M
RSI (14)
47.5
MomentumView details →
1D Return
−2.30%
YTD Return
+17.74%
SummaryUpdated Jun 1, 2026
Cingulate Inc. (NASDAQ:CING) is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Kansas City, Kansas. The company went public in December 2021 and focuses on developing innovative treatments for neurological and psychiatric disorders. Cingulate is currently advancing multiple drug candidates through clinical trials, with its primary focus on attention-deficit/hyperactivity disorder (ADHD) treatments and anxiety disorders.
Similar companies
Latest newsMore news →
Cingulate Inc. reported its financial results for the second quarter ended June 30, 2026.22d agoCingulate Inc. appointed Zhanpeng "Frederick" Jiang as chairman of the Audit Committee of the Board of Directors, effective July 9, 2026.53d agoCingulate Inc. promoted Shane J. Schaffer to Chief Executive Officer and chairman of the Board of Directors, effective July 9, 2026.53d ago